8-K: Kiora Pharmaceuticals Announces 2024 Results and Provides Clinical Development Update

Kiora Pharmaceuticals reports 2024 financial results, highlights progress in retinal disease drug development, and anticipates cash runway into 2027.

Summary

• Kiora Pharmaceuticals announced its 2024 financial results and provided an update on its pipeline of therapeutics for retinal diseases.
• The company received approval to initiate a Phase 2 trial (KLARITY) of KIO-104 for retinal inflammation and a Phase 2 study (ABACUS-2) of KIO-301 in retinitis pigmentosa (RP).
• Kiora received $3.3 million in reimbursed R&D expenses in 2024 from Laboratoires Tha for KIO-301 development.
• The company ended the year with $26.8 million in cash, cash equivalents, and short-term investments, plus $0.9 million in collaboration and tax receivables.
• Kiora expects its cash to fund operations into 2027, excluding potential partnership milestones, beyond the data readouts from KLARITY and ABACUS-2 expected in 2026.
• Net income for 2024 was $3.6 million, compared to a net loss of $12.5 million in 2023, primarily due to $16 million in collaboration revenue from Laboratoires Tha.
• Kiora expects net R&D to increase in 2025 primarily due to costs related to patient enrollment in the KLARITY study.
• G&A expenses in 2025 are expected to remain consistent with expenses from 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the company's progress in clinical trials, strong cash position, and improved financial performance. However, increased R&D expenses and the inherent risks associated with drug development temper the overall sentiment.

Positives

• Approval to initiate Phase 2 trials for both KIO-104 and KIO-301 indicates progress in clinical development.
• Collaboration with Laboratoires Tha provides financial support through reimbursed R&D expenses.
• Strong cash position provides a runway into 2027, allowing for continued development efforts.
• The company achieved net income of $3.6 million in 2024, a significant turnaround from the previous year's net loss.
• The company is refining clinical endpoints that can measure clinically meaningful improvement in patients with no vision or bare light perception.

Negatives

• Net loss was $4.2 million for the fourth quarter of 2024 compared to a net loss of $2.3 million for the fourth quarter of 2023.
• R&D expenses increased for both the fourth quarter and the full year, primarily due to research activities related to KIO-301 and KIO-104.
• G&A expenses increased for both the fourth quarter and the full year.

Risks

• The company's ability to execute on development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora's development-stage products, including KIO-104 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all.
• The sufficiency of existing cash and short-term investments on hand to fund operations for specific periods.
• The ability to timely complete planned initiatives for 2025, including Phase 2 clinical development of KIO-301 and KIO-104.
• The completion of enrollment and the timing of topline results from the ABACUS-2 Phase 2 trial.
• The potential for KIO-301 to be the first treatment options for patients with inherited degenerative diseases like RP.
• The potential for KIO-104 to reduce inflammation.
• The timing of topline results from the Phase 2 KLARITY trial of KIO-104.
• The potential for KIO-104 to apply to other retinal inflammatory diseases.
• Expected trends for research and development and general and administrative spending in 2025.

Future Outlook

Kiora expects its cash to fund operations into 2027, beyond the anticipated 2026 readouts for the KLARITY and ABACUS-2 trials. Net R&D is expected to increase in 2025 due to patient enrollment in the KLARITY study. G&A expenses in 2025 are expected to remain consistent with expenses from 2024.

Management Comments

• Brian M. Strem, Ph.D., President & Chief Executive Officer of Kiora, stated that initiating the KLARITY and ABACUS-2 Phase 2 clinical trials are the company's two greatest priorities for this year, with data expected from both in 2026.
• Melissa Tosca, Kiora's Chief Financial Officer, added that the company ended the year with a runway into 2027, beyond the anticipated 2026 readouts for the KLARITY and ABACUS-2 trials.

Industry Context

Kiora's focus on retinal diseases aligns with the growing demand for treatments in this area, driven by an aging population and increasing prevalence of conditions like retinitis pigmentosa and diabetic macular edema. The company's approach of developing innovative small molecules to target critical pathways underlying retinal diseases positions it within a competitive landscape of companies pursuing various therapeutic modalities, including gene therapy, cell therapy, and biologics.

Comparison to Industry Standards

• Many biotech companies focused on retinal diseases, such as REGENXBIO and Adverum Biotechnologies, are primarily focused on gene therapy approaches.
• Kiora's small molecule approach with KIO-104 and KIO-301 offers a different mechanism of action compared to gene therapy and could potentially address a broader patient population.
• The $26.8 million cash position provides Kiora with a runway comparable to other clinical-stage biotech companies of similar size, allowing them to advance their clinical programs.
• The collaboration with Laboratoires Tha is similar to other partnerships in the biotech industry, where larger companies provide funding and expertise in exchange for potential future commercial rights.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance and progress in clinical development.
• Employees: Positive impact due to continued investment in R&D and potential for career growth.
• Patients: Potential positive impact if KIO-104 and KIO-301 prove to be effective treatments for retinal diseases.
• Partners: Continued collaboration with Laboratoires Tha for KIO-301 development.

Next Steps

• Initiate patient enrollment in the KLARITY Phase 2 clinical trial in the second quarter of 2025.
• Begin dosing the first patient in the ABACUS-2 study following the completion of an ongoing clinical endpoint validation study.
• Continue research and development activities related to KIO-301 and KIO-104.
• Monitor and manage R&D and G&A expenses in 2025.

Key Dates

Keywords

Kiora Pharmaceuticals, KPRX, retinal disease, KIO-301, KIO-104, clinical trials, ABACUS-2, KLARITY, financial results, retinitis pigmentosa, retinal inflammation, biotechnology